Page 12 - Nasdaq Bmea News Today : Breaking News, Live Updates & Top Stories | Vimarsana

REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to...

Biomea Fusion (NASDAQ:BMEA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, “Biomea Fusion Inc. is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecules to treat […]

Shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) have received an average rating of “Buy” from the six brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among […]

Shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) have been assigned an average rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month […]

Biomea Fusion (NASDAQ:BMEA – Get Rating) and RedHill Biopharma (NASDAQ:RDHL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Earnings and Valuation This table compares Biomea Fusion and […]